

CORRECTION

Open Access



Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)

Mélanie Casile^{1,3*}, Gilles Albrand², Clément Lahaye⁷, Benjamin Lebecque^{1,3}, Joévin Besombes^{1,3}, Céline Bourgne^{1,3}, Bruno Pereira⁴, Sandrine Saugues^{1,5}, Caroline Jamot^{1,5}, Eric Hermet⁶ and Marc G. Berger^{1,3,5}

Correction: *BMC Cancer* 24, 661 (2024)
<https://doi.org/10.1186/s12885-024-12415-2>.

The author group above has been updated and the original article [1] has been corrected.

Following publication of the original article [1], it was reported that the third author, Clément Lahaye, was erroneously omitted from the author group. Clément Lahaye is affiliated with Unité mobile de Gériatrie, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Published online: 05 July 2024

The online version of the original article can be found at <https://doi.org/10.1186/s12885-024-12415-2>.

*Correspondence:

Mélanie Casile

mcasile@chu-clermontferrand.fr

¹Biological Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

²Geriatric Evaluation and Management unit, Antoine Charial Hospital, Francheville, Lyon, France

³EA 7453 CHELTER, University of Clermont Auvergne, Clermont-Ferrand, France

⁴Biostatistics Unit, Clinical Research and Innovation Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

⁵Biological Resources Centre – Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France

⁶Clinical Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

⁷Unité mobile de Gériatrie, CHU Clermont-Ferrand, Clermont-Ferrand, France

References

1. Casile M, Albrand G, Lahaye C, et al. Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial). *BMC Cancer*. 2024;24:661. <https://doi.org/10.1186/s12885-024-12415-2>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.